Clinical Trials Logo

Clinical Trial Summary

Sensenbrenner syndrome, also known as cranioectodermal dysplasia (CED), is a rare autosomal-recessive disorder belonging to the ciliopathy group of diseases. It is characterized by a facial dysmorphism, abnormal bone development and ectodermal defects including dental anomalies. CED is a heterogeneous condition with significant phenotypic and molecular variability, whose spectrum may include cases of renal impairment, hepatic fibrosis, retinitis pigmentosa and/or brain anomalies. In many cases, patients develop chronic kidney disease (CKD) due to nephronophthisis between 2 and 6 years of age. The aim of this retrospective study is to better understand the characteristics of this syndrome and to find prognostic factors of CKD. We make the hypothesis that an early diagnosis of the syndrome would lead to a better global management of patients (quality of life, delayed onset of end-stage renal disease).


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04184531
Study type Observational
Source Hospices Civils de Lyon
Contact Federico DI ROCCO, Pr
Phone 4 72 35 75 72
Email federico.dirocco@chu-lyon.fr
Status Not yet recruiting
Phase
Start date January 2020
Completion date July 2020